MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells

Cancer Genetics and Cytogenetics

Volumn 201, Issue 2, 2010, Pages 102-110

  Lacunza, E ^a   Baudis, M ^b   Colussi, A G ^a   Segal Eiras, A ^a   Croce, M V ^a   Abba, M C ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EPIGENETICS; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 77955259812     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.05.015     Document Type: Article

References (41)

1. Debatisse M., Malfoy B. Gene amplification mechanisms. Adv Exp Med Biol 2005, 570:343-361.
2. Chen L.C., Manjeshwar S., Lu Y., Moore D., Ljung B.M., Kuo W.L., et al. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998, 58:3677-3683.
3. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
4. Bautista S., Theillet C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 1998, 22:268-277.
5. Bärlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M.L., et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000, 92:1252-1259.
6. Luoh S., Venkatesan N., Tripathi R. Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage. Oncogene 2004, 23:1354-1363.
7. Al-Kuraya K., Schraml P., Torhorst J., Tapi C., Zaharieva B., Novotny H., et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004, 64:8534-8540.
8. Knuutila S., Autio K., Aalto Y. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 2000, 157:689.
9. Pollack J.R., Sørlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E.R., et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002, 99:12963-12968.
10. Fridlyand J., Snijders A.M., Ylstra B., Li H., Olshen A., Segraves R., et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96.
11. Gendler S.J. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001, 6:339-353.
12. Schroeder J.A., Masri A.A., Adriance M.C., Tessier J.C., Kotlarczyk K.L., Thompson M.C., et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23:5739-5747.
13. Raina D., Ahmad R., Joshi M.D., Yin L., Wu Z., Kawano T. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009, 69:5133-5141.
14. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4:45-60.
15. Li Y., Yu W.H., Ren J., Chen W., Huang L., Kharbanda S., et al. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res 2003, 1:765-775.
16. Huang L., Chen D., Liu D., Yin L., Kharbanda S., Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005, 65:10413-10422.
17. Ahmad R., Raina D., Trivedi V., Ren J., Rajabi H., Kharbanda S., et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol 2007, 9:1419-1427.
18. Gaemers I.C., Vos H.L., Volders H.H., van der Valk S.W., Hilkens J. A stat-responsive element in the promoter of the episialin/ MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001, 276:6191-6199.
19. Shiraga T., Winpenny J.P., Carter E.J., McCarthy V.A., Hollingsworth M.A., Harris A. MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene. Exp Cell Res 2005, 308:41-52.
20. Zaretsky J.Z., Barnea I., Aylon Y., Gorivodsky M., Wreschner D.H., Keydar I. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer 2006, 5:57.
21. Abba M.C., Nunez M.I., Colussi A.G., Croce M.V., Segal-Eiras A., Aldaz C.M. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. Breast Cancer Res 2006, 8:R64.
22. Yamada N., Nishida Y., Tsutsumida H., Hamada T., Goto M., Higashi M., et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modifications in cancer cells. Cancer Res 2008, 68:2708-2716.
23. Bièche I., Lidereau R. A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogenet 1997, 98:75-80.
24. Takano M., Fujii K., Kita T., Kikuchi Y., Uchida K. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol Rep 2004, 12:1177-1182.
25. Wreesmann V.B., Sieczka E.M., Socci N.D., Hezel M., Belbin T.J., Childs G., et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004, 64:3780-3789.
26. Myllykangas S., Junnila S., Kokkola A., Autio R., Scheinin I., Kiviluoto T., et al. Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 2008, 123:817-825.
27. Chin S.F., Teschendorff A.E., Marioni J.C., Wang Y., Barbosa-Morais N.L., Thorne N.P., et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007, 8:R215.
28. Abba M.C., Drake J.A., Hawkins K.A., Hu Y., Sun H., Notcovich C., et al. Trancriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 2004, 6:R499-R513.
29. Abba M.C., Sun H., Hawkins K.A., Drake J.A., Hu Y., Nunez M.I., et al. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007, 5:881-890.
30. Abba M.C., Fabris V.T., Hu Y., Kittrell F.S., Cai W., Donehower L.A., et al. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 2007, 67:4104-4112.
31. Lyng M.B., Laenkholm A., Pallisgaard N., Ditzel H.J. Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer 2008, (8):20.
32. Croce M.V., Isla-Larrain M., Remes-Lenicov F., Colussi A.G., Lacunza E., Kim K.C., et al. MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol 2006, 21:849-855.
33. La Rosa P., Viara E., Hupé P., Pierron G., Liva S., Neuvial P., et al. VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006, 22:2066-2073.
34. Baudis M., Cleary M.L. Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001, 17:1228-1229.
35. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
36. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 2007, 7:226.
37. Rosa F.E., Silveira S.M., Silveira C.G., Bérgamo N.A., Neto F.A., Domingues M.A., et al. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 2009, 9:90.
38. Matsukita S., Nomoto M., Kitajima S., Tanaka S., Goto M., Irimura T., et al. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 2003, 42:26-36.
39. Rakha E.A., Boyce R.W., Abd El-Rehim D., Kurien T., Green A.R., Paish E.C., et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005, 18:1295-1304.
40. Croce M.V., Isla-Larrain M.T., Demichelis S.O., Gori J.R., Price M.R., Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003, 81:195-207.
41. Zhou Y., Luoh S., Zhang Y., Watanabe C., Wu T.D., Ostland M., et al. Genome-wide identification of chromosomal regions of increased tumor expression by transcriptome analysis. Cancer Res 2003, 63:5781-5784.